Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.

Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA.

Drug Saf. 2006;29(8):687-96.

PMID:
16872242
2.

Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A.

Drug Saf. 2005;28(10):917-24.

PMID:
16180941
3.

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.

Cochrane Database Syst Rev. 2014 Oct 23;(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Review.

PMID:
25340915
4.

A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.

Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.

Drug Saf. 2005;28(9):803-16.

PMID:
16119973
6.
7.

Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

Layton D, Wilton LV, Shakir SA.

Eur J Clin Pharmacol. 2004 Sep;60(7):489-501.

PMID:
15278327
8.
9.

A case report on toxic epidermal necrolysis with etoricoxib.

Kameshwari JS, Devde R.

Indian J Pharmacol. 2015 Mar-Apr;47(2):221-3. doi: 10.4103/0253-7613.153436.

10.

Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature.

Ward KE, Archambault R, Mersfelder TL.

Am J Health Syst Pharm. 2010 Feb 1;67(3):206-13. doi: 10.2146/ajhp080603. Review.

PMID:
20101062
11.

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.

Drug Saf. 2006;29(7):621-32.

PMID:
16808554
13.

COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.

Durrieu G, Olivier P, Montastruc JL; French networks of Pharmacovigilance centers.

Eur J Clin Pharmacol. 2005 Sep;61(8):611-4. Epub 2005 Aug 24.

PMID:
16133552
14.
15.

Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.

Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.

Clin Ther. 2010 Jul;32(7):1294-303. doi: 10.1016/j.clinthera.2010.07.005.

PMID:
20678677
16.
17.

Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

Andersohn F, Schade R, Suissa S, Garbe E.

Stroke. 2006 Jul;37(7):1725-30. Epub 2006 May 25.

18.
19.
20.

Renal failure associated with the use of celecoxib and rofecoxib.

Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J.

Drug Saf. 2002;25(7):537-44. Review.

PMID:
12093311

Supplemental Content

Support Center